Skip to main content
Premium Trial:

Request an Annual Quote

Selventa, Janssen Partner on Immunological Diseases

NEW YORK (GenomeWeb News) – Selventa today announced a research agreement with Janssen Research & Development in immunological diseases.

The deal includes the development of disease models to shed information about disease-relevant mechanisms and to identify new drug discovery opportunities, Selventa said. Aside from saying the deal is multi-year the company did not disclose the terms.

Selventa and an affiliate of Janssen R&D earlier collaborated on a joint publication that sought to identify genes associated with intestinal permeability post anti-TNF therapy in ulcerative colitis, David de Graaf, president and CEO of Selventa said in a statement.

"Building comprehensive disease models and investigating different molecular mechanisms may provide key data-driven foundation for appropriate selection of druggable mechanisms within a disease," he said.

Selventa, a life science data analysis firm based in Cambridge, Mass., raised $5 million in late 2011.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.